HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David P. Taggart Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taggart, D. P. Search for Related Content PubMed PubMed Citation Articles by Taggart, D. P. Related Collections Extracorporeal circulation Lung - basic science

Ann Thorac Surg 2001;71:238-242
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Effects of a platelet-activating factor antagonist on lung injury and ventilation after cardiac operation

^a Oxford Heart Centre, John Radcliffe Hospital, Oxford, England, UK

Accepted for publication April 26, 2000.

Address reprint requests to Dr Taggart, Oxford Heart Centre, John Radcliffe Hospital, Oxford OX3 9DU, England
e-mail: david.taggart{at}orh.anglox.nhs.uk

Background. Platelet-activating factor is a mediator of lung injury during cardiac operation. Platelet-activating factor antagonists reduce lung injury in animal models of cardiopulmonary bypass but there is no confirmatory evidence in clinical practice.

Methods. The effect of a low or high dose of a platelet-activating factor antagonist (Lexipafant) was assessed in a single center, double-blind, placebo-controlled, parallel group study. One hundred fifty patients undergoing coronary artery bypass grafting were randomized by minimization into three groups to receive placebo infusion, 10 or 100 mg of lexipafant for over 24 hours. Serial arterial oxygen and carbon dioxide tension, alveolar arterial oxygen gradient, and percent saturation were measured before operation and at 1, 6, 24, 48 hours, and 5 days after operation.

Results. Patient groups were similar with respect to age, sex, body surface area, and urgency of operation. Likewise, the groups were similar with respect to duration of cardiopulmonary bypass and the number and type of grafts. Maximum lung injury occurred at 48 hours when the arterial oxygen tension and percent saturation reached a nadir (both p < 0.001) accompanied by the maximum increase in the alveolar arterial gradient (p < 0.001). All measurements demonstrated partial recovery by 5 days but remained significantly (p < 0.001) impaired in comparison to baseline values. Duration of ventilation was similar in all groups. Lexipafant, at low or high dose, did not moderate lung injury after cardiopulmonary bypass and did not influence the duration of postoperative ventilation.

Conclusions. Despite experimental and clinical evidence implicating platelet-activating factor in the pathophysiology of lung injury after cardiopulmonary bypass, no beneficial effect of a platelet-activating factor antagonist on lung function or ventilation could be demonstrated in this clinical trial.

This article has been cited by other articles:

				S. M. Browne, P. W. Halligan, D. T. Wade, and D. P. Taggart Postoperative hypoxia is a contributory factor to cognitive impairment after cardiac surgery J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1061 - 1064. [Abstract] [Full Text] [PDF]

				M J Naik, Y Abu-Omar, A Alvi, N Wright, A Henderson, K Channon, J C Forfar, and D P Taggart Total arterial revascularisation as a primary strategy for coronary artery bypass grafting Postgrad. Med. J., January 1, 2003; 79(927): 43 - 48. [Abstract] [Full Text] [PDF]